1. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy
- Author
-
Cedric Richlitzki, Marcel Wiesweg, Martin Metzenmacher, Nika Guberina, Christoph Pöttgen, Hubertus Hautzel, Wilfried E. E. Eberhardt, Kaid Darwiche, Dirk Theegarten, Clemens Aigner, Servet Bölükbas, Martin Schuler, Martin Stuschke, and Maja Guberina
- Subjects
C-reactive protein (CRP) ,Stage III non-small cell lung cancer (NSCLC) ,Definitive radiochemotherapy ,Laboratory values ,Overall survival ,ESPATUE trial ,Medicine ,Science - Abstract
Abstract To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation. Cross validated classifiers including biomarkers in addition to important clinical parameters were compared with classifiers containing the clinical parameters alone. An increased C-reactive protein (CRP) value in the final week of radiotherapy was found as a prognostic factor for overall survival, both as a continuous (HR 1.099 (1.038–1.164), p
- Published
- 2024
- Full Text
- View/download PDF